Following incubation with 50% chamber fluid, the CD11b activation epitope was significantly induced compared with cells incubated with the corresponding serum. Furthermore, the expression induced by chamber fluid corresponded to the expression induced by 100 ng/ml recombinant IL-8. The result is in line with previous findings indicating an

increased expression of CBRM1/5 after 10 min of incubation with relatively strong activators such as phorbol 12-myristate 13-acetate (PMA) and N-formylmethionyl leucyl phenylalanine (fMLP) [27], as well as weaker activators such as IL-8, C3a or platelet-activating factor (PAF) [28]. Interestingly, www.selleckchem.com/products/sch772984.html in our model, which is based on mediators released during a physiological response, IL-8 was the sole mediator correlating to CD11b activation. To further examine the correlation between IL-8 and CD11b activation, the expression of CD11b activation epitope was assessed following in vitro incubation with recombinant IL-8 corresponding to the concentration in serum and chamber fluid. The expression of the activation epitope was concentration dependent and increased gradually at levels corresponding to chamber fluid. Interestingly, in a former publication, a single dose of 10 ng/ml IL-8 induced

an almost identical expression of CBRM1/5 as in the Selleck Atezolizumab present article using the same concentration [28]. In this article, we demonstrate for the first time a concentration-dependent induction of the CD11b activation epitope by use of both endogenous and recombinant IL-8. Recombinant IL-8 required 10 times

higher the concentration of IL-8 in chamber fluid to induce a similar activation of CD11b. This could be explained by an increased biological activity of IL-8 in vivo, which has been demonstrated following gelatinase-mediated truncations [29] or by the combined action of other inflammatory mediators, not by themselves correlating to the CBRM1/5 expression. In summary, the concentration of IL-8 was a major determinant for neutrophil transmigration both in vivo and in vitro. One Arachidonate 15-lipoxygenase possible mechanism could be through regulation of the activation epitope on CD11b, and the present data on an IL-8 dose-dependent activation of CD11b support this view. Endogenous IL-8, compared with recombinant, mounted an enhanced response, probably reflecting an increased potency of in vivo IL-8. We, therefore, suggest IL-8 to be a major determinant for neutrophil CD11b activation and extravasation. The authors would like to thank Anette Bygden-Nylander for assistance with the skin blister method. The study was supported by unrestricted grants from Karolinska Institute and Hesselman Foundation. JMP, JL and SHJ wrote the paper; JMP conceived, designed and performed the experiments; JMP and JL analysed the data; and SHJ contributed to reagents.